Terms: = Ovarian cancer AND MYCL, LMYC, 4610, MYCL1, ENSG00000116990
10 results:
1. Comparative study on the mutation spectrum of L-MYC and C-MYC genes of blood cfDNA in patients with ovarian cancer and healthy females.
Shabir S; Asiaf A
J Obstet Gynaecol Res; 2023 Dec; 49(12):2894-2904. PubMed ID: 37827180
[TBL] [Abstract] [Full Text] [Related]
2. A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
Bauer TM; Moore KN; Rader JS; Simpkins F; Mita AC; Beck JT; Hart L; Chu Q; Oza A; Tinker AV; Imedio ER; Kumar S; Mugundu G; Jenkins S; Chmielecki J; Jones S; Spigel D; Fu S
Target Oncol; 2023 Jul; 18(4):517-530. PubMed ID: 37278879
[TBL] [Abstract] [Full Text] [Related]
3. Oleic acid stimulates cell proliferation and BRD4-L-MYC-dependent glucose transporter transcription through PPARα activation in ovarian cancer cells.
Kado T; Kusakari N; Tamaki T; Murota K; Tsujiuchi T; Fukushima N
Biochem Biophys Res Commun; 2023 May; 657():24-34. PubMed ID: 36965420
[TBL] [Abstract] [Full Text] [Related]
4. Multiple primary non-breast tumors in breast cancer survivors.
Corso G; Veronesi P; Santomauro GI; Maisonneuve P; Morigi C; Peruzzotti G; Intra M; Sacchini V; Galimberti V
J Cancer Res Clin Oncol; 2018 May; 144(5):979-986. PubMed ID: 29502170
[TBL] [Abstract] [Full Text] [Related]
5. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
[TBL] [Abstract] [Full Text] [Related]
6. A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated cancers.
Jung M; Russell AJ; Liu B; George J; Liu PY; Liu T; DeFazio A; Bowtell DD; Oberthuer A; London WB; Fletcher JI; Haber M; Norris MD; Henderson MJ
Cancer Res; 2017 Feb; 77(4):971-981. PubMed ID: 27923830
[TBL] [Abstract] [Full Text] [Related]
7. MicroRNA related polymorphisms and breast cancer risk.
Khan S; Greco D; Michailidou K; Milne RL; Muranen TA; Heikkinen T; Aaltonen K; Dennis J; Bolla MK; Liu J; Hall P; Irwanto A; Humphreys K; Li J; Czene K; Chang-Claude J; Hein R; Rudolph A; Seibold P; Flesch-Janys D; Fletcher O; Peto J; dos Santos Silva I; Johnson N; Gibson L; Aitken Z; Hopper JL; Tsimiklis H; Bui M; Makalic E; Schmidt DF; Southey MC; Apicella C; Stone J; Waisfisz Q; Meijers-Heijboer H; Adank MA; van der Luijt RB; Meindl A; Schmutzler RK; Müller-Myhsok B; Lichtner P; Turnbull C; Rahman N; Chanock SJ; Hunter DJ; Cox A; Cross SS; Reed MW; Schmidt MK; Broeks A; Van't Veer LJ; Hogervorst FB; Fasching PA; Schrauder MG; Ekici AB; Beckmann MW; Bojesen SE; Nordestgaard BG; Nielsen SF; Flyger H; Benitez J; Zamora PM; Perez JI; Haiman CA; Henderson BE; Schumacher F; Le Marchand L; Pharoah PD; Dunning AM; Shah M; Luben R; Brown J; Couch FJ; Wang X; Vachon C; Olson JE; Lambrechts D; Moisse M; Paridaens R; Christiaens MR; Guénel P; Truong T; Laurent-Puig P; Mulot C; Marme F; Burwinkel B; Schneeweiss A; Sohn C; Sawyer EJ; Tomlinson I; Kerin MJ; Miller N; Andrulis IL; Knight JA; Tchatchou S; Mulligan AM; Dörk T; Bogdanova NV; Antonenkova NN; Anton-Culver H; Darabi H; Eriksson M; Garcia-Closas M; Figueroa J; Lissowska J; Brinton L; Devilee P; Tollenaar RA; Seynaeve C; van Asperen CJ; Kristensen VN; ; ; Slager S; Toland AE; Ambrosone CB; Yannoukakos D; Lindblom A; Margolin S; Radice P; Peterlongo P; Barile M; Mariani P; Hooning MJ; Martens JW; Collée JM; Jager A; Jakubowska A; Lubinski J; Jaworska-Bieniek K; Durda K; Giles GG; McLean C; Brauch H; Brüning T; Ko YD; ; Brenner H; Dieffenbach AK; Arndt V; Stegmaier C; Swerdlow A; Ashworth A; Orr N; Jones M; Simard J; Goldberg MS; Labrèche F; Dumont M; Winqvist R; Pylkäs K; Jukkola-Vuorinen A; Grip M; Kataja V; Kosma VM; Hartikainen JM; Mannermaa A; Hamann U; Chenevix-Trench G; Blomqvist C; Aittomäki K; Easton DF; Nevanlinna H
PLoS One; 2014; 9(11):e109973. PubMed ID: 25390939
[TBL] [Abstract] [Full Text] [Related]
8. Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas.
Wu R; Lin L; Beer DG; Ellenson LH; Lamb BJ; Rouillard JM; Kuick R; Hanash S; Schwartz DR; Fearon ER; Cho KR
Am J Pathol; 2003 May; 162(5):1603-10. PubMed ID: 12707044
[TBL] [Abstract] [Full Text] [Related]
9. Frequent loss of heterozygosity on chromosome 18 in ovarian adenocarcinoma which does not always include the DCC locus.
Chenevix-Trench G; Leary J; Kerr J; Michel J; Kefford R; Hurst T; Parsons PG; Friedlander M; Khoo SK
Oncogene; 1992 Jun; 7(6):1059-65. PubMed ID: 1594239
[TBL] [Abstract] [Full Text] [Related]
10. Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines.
Tyson FL; Boyer CM; Kaufman R; O'Briant K; Cram G; Crews JR; Soper JT; Daly L; Fowler WC; Haskill JS
Am J Obstet Gynecol; 1991 Sep; 165(3):640-6. PubMed ID: 1679963
[TBL] [Abstract] [Full Text] [Related]
